Cart
sales@molnova.com
BI-1347
CAS No. 2163056-91-3
BI-1347 ( BI1347 )
Catalog No. M13451 CAS No. 2163056-91-3
BI-1347 is a potent, selective inhibitor of CDK8/cyclinC with IC50 of 1 nM。
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 72 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 228 | In Stock |
|
| 50MG | 417 | In Stock |
|
| 100MG | 614 | In Stock |
|
| 500MG | 1287 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBI-1347
-
NoteResearch use only, not for human use.
-
Brief DescriptionBI-1347 is a potent, selective inhibitor of CDK8/cyclinC with IC50 of 1 nM。
-
DescriptionBI-1347 is a potent, selective inhibitor of CDK8/cyclinC with IC50 of 1 nM; BI-1347 shows tumor growth inhibition in an in vivo xenograft model, BI-1347 is an excellent small molecule tool inhibitor for testing biological hypotheses in vitro and in vivo.
-
SynonymsBI1347
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK8
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2163056-91-3
-
Formula Weight356.43
-
Molecular FormulaC22H20N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 120 mg/mL (336.68 mM), Need ultrasonic and warming （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(N(C)C)CN1N=CC(C2=CC=C(C3=CN=CC4=C3C=CC=C4)C=C2)=C1
-
Chemical Name2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
AZD 5597
A highly potent cyclin-dependent kinase (CDK) inhibitor with IC50 of 2 nM for both CDK1 and CDK2; exhibits anti-proliferative activity against LoVo cells with IC50 of 39 nM.
-
1NM-PP1
1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).
-
Dalpiciclib
Dalpiciclib is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4?nM and 9.9?nM, respectively.
